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Abstract
Ovarian cancer is known to be the most lethal gynecologic cancer. It has been
reported that Glypican-3 (Gpc3) expression induces immune responses, promotes
the progression in ovarian cancer. Then, we focused on this Gpc3 gene silencing,
tried to prepare siRNA delivery system. In this chapter, we introduce one of the
therapeutic proposals in terms of novel drug delivery system using siRNA as a
targeting medicine. This chapter introduces our works about preparation of siRNA-
PLGA hybrid micelles to deliver the siRNA into the ovarian cancer cells and to
evaluate gene silencing effects in mice model. As a result, siRNA-PLGA hybrid
micelles were shown to effectively inhibit Gpc3 expression in vitro. In addition,
siRNA-PLGA hybrid micelles also decreased the number of tumor nodes in the
mesentery in vivo. These results suggested that Gpc3 could be a target molecule for
ovarian cancer treatment and siRNA-PLGA hybrid micelles could be an effective
siRNA delivery tool even in vivo.
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1. Introduction
Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy.
EOC accounts for about 90% of all ovarian cancers and distributed over the most
common histotypes: high-grade serous (HGSC, 70%), low-grade serous (LGSC, <
5%), endometrioid (EC, 10%), mucinous (MC, 3–4%) and clear cell ovarian carci-
noma (CCC, 10%) [1]. Five-year survival rates differ significantly across the
histotypes, with drastically lower survival rates for serous carcinoma (SC (HGSC
and LGSC), 43%) compared with EC (82%), MC (71%) and CCC (66%) in the USA.
CCC is a comparatively rare tumor, depending on the geographic location. In west
countries, OCCC represents <10% of all EOC. In contrast, the incidence of CCC
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was reportedly 25% of EOC in Japan. The high number of patients (80%) with SC is
diagnosed at advanced stages (stages III and IV). While, CCC which has the second
number of patients (25%) after SC, is predominantly diagnosed at stage I (65%) [2].
Thus, CCC has different character compared with SC. Five-year survival rate at
stage I for SC and CCC is same (80%). While, five-year survival rate at stage IV for
SC is 40% and stage I of CCC is 25%. CCC has a very poor prognosis. One of the
reasons is that CCC is associated with greater chemoresistance and a poorer prog-
nosis compared with other EOC subtypes. Particularly for recurrent CCC, the
response rate (RR) to salvage chemotherapy was extremely low. Previous studies
have indicated that high L-type amino acid transporter 1 (LAT1), which belongs to
system L, a Na+-independent carrier that transports large neutral amino acids,
expression was associated with poorer prognosis and chemoresistance in CCC [3].
Furthermore, hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute
for the chemoresistance to platinum-based antineoplastic agents of CCC through
the intrinsically increased glutathione (GSH) bioavailability [4]. Therefore, novel
and innovative strategies are required to improve outcomes for patients with CCC
that is refractory to chemotherapy.
Glypican-3 (GPC3) is a member of the glypican family of heparan sulfate pro-
teoglycans. GPC3 regulates cell proliferation signals by binding growth factors
such as Wnt, fibroblast growth factor, and insulin-like growth factor and plays an
important role in the proliferation and differentiation of embryonic cells [5–7].
GPC3 is expressed in various fetal tissues (liver, lung, kidney, and placenta) but is
not detected in normal postnatal tissue due to DNA methylation-induced epige-
netic silencing [8, 9]. While, previous studies showed that GPC3 was
overexpressed in several malignant tumors, including hepatocellular carcinoma
(HCC), CCC and melanoma. Particularly, GPC3 is detected in ≥80% of patients
with HCC caused by hepatitis B or C [10, 11]. The function of membrane-
anchored GPC3 in these cancers is unknown, but it is likely involved in the
neoplastic transformation of HCC [12]. Membrane-bound GPC3 can be cleaved
and secreted into the blood. Mammalian GPC family members are cleaved at GPI
anchor level by endogenous GPI phospholipase D [13]. Thus, various forms of
GPC3 protein are present in blood, although their functions remain unclear. Given
these features, GPC3 is useful not only as a target for cancer immunotherapy but
also as a novel tumor marker.
Small interfering or silencing RNA (siRNA) technologies are based on the inhi-
bition of gene expression or translation by siRNAs targeting messenger RNA selec-
tively [14]. Gene interference therapy using siRNA has great potential for treatment
of wide variety of diseases [15], ranging from cancer [16–19] to viral infection
[20, 21] and brain disorder [22, 23]. The benefit of applying this technology to
cancer therapy is that siRNA can target genes which are specific for tumor cells,
leaving healthy, non-tumor tissue unaffected. Despite their medical potential, the
clinical translation of siRNA technologies has up to now been limited. This limited
progress is due to the difficulties of delivering siRNA in vivo. Unprotected siRNAs
are easily degraded in the bloodstream, and siRNAs alone do not translocate across
cell membrane [24]. In addition, it has been reported that siRNAs can be immuno-
genic [25]. Therefore, safe and efficient carriers must be developed for siRNA
delivery to protect siRNA from nuclease action and at the same time triggers
intracellular uptake in vivo [26, 27].
In our previous study, we prepared slow release formulation using biodegrad-
able polymer (poly(lactide-co-glycolide), PLGA) such as micro-/nano particles
[28]. Recently, we engaged to prepare the siRNA delivery system using PLGA for
anti-metastasis therapy.
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In this chapter, we report the therapeutic effect of Gpc3 gene silencing in
ovarian cancer, and introduce the finding about a novel siRNA delivery system of
micelles for nucleic acid therapy based on our data [29].
2. Effect of anti-metastasis in ovarian cancer caused by Glypican-3 gene
silencing
2.1 Role of Grypican-3 in ovarian cancer
GPC3, 55–65 kDa protein consisting of 580 amino acids, is a heparan sulfate
chain proteoglycan (HSPGs) bound to cell membrane by a glycosylphosphatidy-
linositol (GPI) anchor. This protein is expressed in the liver and kidney of healthy
fetuses but is hardly expressed in adults, except in the placenta. Loss of function
mutations of GPC3 leads to Simpson-Golabi-Behmel syndrome (SGBS), a rare X-
linked disorder (X chromosome, Xq26) with significant overgrowth [5], which has
also been observed in GPC3-null mice [30] because the gene shows high homology
between humans and mice. GPC3 is expressed ubiquitously in the embryo but is
reduced in the central nervous system (CNS) in adults [31]. Thus, GPC3 is consid-
ered to be one of the factors affecting prenatal development and metabolism origi-
nally. On the other hand, GPC3 is especially overexpressed in HCC [10, 11], CCC
[32, 33], melanoma [34], and lung cancer [35]. Although the precious function of
GPC3 remains unclear, it has been strongly suggested that it is related to the
malignant transformation, accelerating cell growth and increasing inflammatory
reaction [36].
The Wnt/Frizzled/β-catenin pathway is activated in about 50% of HCCs. Wt3a
has been shown to mediate the GPC3-induced growth of HCCs via the canonical
Wnt/β-catenin pathway [6, 37]. Sulfated heparan sulfate glycosaminoglycan
(HSGAG) chains of GPC3 and other HSPGs are potential substrates for desulfation
at the 6-O position by human sulfate 2 (SULF2). It has been reported that SULF2
activates Wnt/β-catenin signaling in HCC cells, and this process is GPC3-dependent
and can be independent of exogenous Wnts [38]. In a previous study, a human
monoclonal antibody against GPC3 inhibited Wnt3a/β-catenin signaling in HCC
cells and antitumor activity in vivo [39]. Furthermore, blocking the heparan sulfate
chains on GPC3 with human monoclonal antibody against GPC3 also reduced c-Met
activation in hepatocyte growth factor (HGF)-treated HCC cells and 3D-cultured
spheroids. GPC3 is involved in HCC cell migration and motility through HS chain-
mediated cooperation with the HGF/Met pathway [40].
Although the role of GPC3 in HCC has been reported little by little, the role of
GPC3 in ovarian cancer, especially CCC expressed GPC3, has been remained
unclear. So recurrent or persistent CCC has been reported as having a potentially
chemoresistant phenotype against conventional cytotoxic agents, leading to poorer
prognosis. Thus, novel treatment approaches must be adopted for CCC. With com-
pelling evidence that EOC is an immunogenic tumor, immunotherapeutic
approaches are currently being evaluated and should be optimized based on
histology-specific features. Previous research also suggested that GPC3 peptide
vaccinations may hold a significant impact to prolong survival of patients with
refractory CCC, allowing them to maintain quality of life with no serious
toxicities [41].
Based on these, we focused on knocking down of GPC3 gene therapy for ovarian
cancer using siRNA which can be expected to be effective in clinical practice. Then,
we evaluated the efficiency of siRNA-PLGA hybrid micelles targeted to Gpc3 on
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ovarian cancer in vitro and examined its antitumor effects in vivo in a mouse
peritoneal dissemination model.
2.2 Effect of anti-metastasis caused by knocking down of Grypican-3 using
LPEI coating siRNA-PLGA hybrid micelles in vivo
The synthesis of siRNA-PLGA hybrid was described briefly as follows. PLGA
was activated by DCC and NHS. Activated PLGA reacted with 3-(2-pyridyldithio)
propionyl hydrazide (PDPH) as a cross-linker. After PDPH activated, PLGA
(PLGA-PDPH) was used for siRNA conjugation. A thiol-modified double-strand
siRNA was reacted with PLGA-PDPH, siRNA-PLGA hybrid was synthesized via a
disulfide exchange reaction. The synthesized siRNA-PLGA hybrid conjugates spon-
taneously formed self-assembled micelles in aqueous solutions, resulting to form
micelle with siRNA side facing the outer shell as shown in Figure 1A and C.
Furthermore, we also prepared liner polyethylenimine (LPEI)-coated siRNA-PLGA
micelles, its surface was positive charged by cationic polymer, to increase the
efficiency of intracellular uptake as shown in Figure 1D.
Measurement of critical micelle concentration (Figure 2) and distribution of
particle (Figure 3) were performed to evaluate the physical properties of micelles.
The mean diameter and zeta potential of siRNA-PLGA hybrid micelles were about
110 nm and about 40 mV, respectively. The zeta potentials of siRNA-PLGA
hybrid micelle were changed from negative charge to positive charge by LPEI
coating.
Until now, the best agents for siRNA delivery are cationic lipids and polycations,
i.e. polyelectrolytes bearing multiple positive charges to increase intracellular
uptake in vivo [42, 43]. From these previous data, LPEI coating micelle can be
expected its clinical potential in vivo because positive charge caused by LPEI makes
micelles easy to be taken into the cell.
The GPC3 levels in HM-1 cell line, which is mouse ovarian cancer cell line,
treated with siRNA-PLGA hybrid micelles were then evaluated by western blotting.
Figure 1.
(A) and (B) Structure of siRNA-PLGA hybrid and Fab’-PLGA hybrid via a cleavable disulfide linkage.
(C)–(E) Schematic diagram for siRNA-PLGA hybrid micelle structure in an aqueous environment.
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As shown in Figure 4, siRNA-PLGA hybrid micelles significantly suppressed GPC3
expression compared with the control.
Assessment of antitumor effects of these micelles in a murine peritoneal dis-
semination model was performed by intraperitoneal (i.p.) injection as topical treat-
ment. In general, topical administration is often more effective because it is easy to
react since the medicine is close to the disease lesion [44]. The number of dissem-
inated nodules and the peritoneal fluid volumes were evaluated at 15 days after
injection of the HM-1 cells. As shown in Figure 5, the number of disseminated
nodules and the volume of peritoneal fluid siRNA-PLGA hybrid micelle-treated
groups were significantly low compared with the control. Next, GPC3 levels in the
cell lysates of peritoneal cells collected from the peritoneal fluid were evaluated by
western blotting.
As shown in Figure 6, the levels of IFN-γ, IL-6, and TNF-α in mice treated with
uncoated and LPEI-coated siRNA-PLGA hybrid micelles were significantly
suppressed compared with the control. GPC3 expression in the lymphocytes such as
B cells, T cells and macrophages in the peritoneal fluid of mice, was detected by
western blotting. From these results, there is a possibility that the therapeutic effect
was induced by GPC3 gene knockdown of not only cancer cell but also lymphocytes
in the peritoneal fluid as the additive effects.
Figure 2.
Critical micelle concentration (CMC) detected by measuring the relative excitation intensity ratio of pyrene at
emission of 329 nm and 338 nm (I338/I329).
Figure 3.
Size distribution of siRNA-PLGA hybrid micelles.
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Figure 4.
Western blot analysis of GPC3levels in HM-1 cells treated with siRNA-PLGA hybrid micelles in vitro. Data
represent the mean  SD (n = 3). **p < 0.01 versus the control group (Bonferroni test/ANOVA). Cited from
Ref. [29]. Reprinted with permission from Elsevier.
Figure 5.
Anti-metastasis effects of siRNA-PLGA micelles in a mouse peritoneal dissemination model. Representative
images of the mesentery after laparotomy. Cited from Ref. [29]. Reprinted with permission from Elsevier.
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2.3 Recognition of cancer cell using Fab0-PLGA/siRNA-PLGA hybrid mixed
micelle in vitro
In previous study, we reported that Gpc3 knocking down using siRNA-PLGA
hybrid micelle by intraperitoneal injection was effective to suppress the metastasis
in peritoneal dissemination of ovarian cancer mice model [29]. However, it is
Figure 6.
Effect of GPC3 knockdown caused by treatment with siRNA-PLGA micelles on the secretion of IFN-γ, IL-6,
TNF-α in the peritoneal fluid in a mouse peritoneal dissemination model. Data represent the mean  SD
(n = 5). **p < 0.01 versus the control group (Bonferroni test/ANOVA). Cited from Ref. [29]. Reprinted with
permission from Elsevier.
Figure 7.
Efficiency of intracellular uptake of Fab0-PLGA/–Alexa 488 labeling siRNA-PLGA hybrid mixed micelles
in vitro by flow cytometry analysis.
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necessary to develop a carrier which is “targeting” and “systemically administable”.
That is why, we prepared Fab0-PLGA/siRNA-PLGA mixed micelle to recognize the
target cell. Fab0-PLGA hybrid was synthesized in a same method as siRNA-PLGA
hybrid was synthesized. The drug design was described in Figure 1B and E.
As shown in Figure 7, in vitro experiment, intracellular uptake of siRNA using
Fab0-PLGA/siRNA-PLGA mixed micelle was significantly increased compared with
control. In particular, cytotoxicity was accelerated caused by treatment with Fab0-
PLGA/siRNA-PLGA mixed micelle compared with siRNA-PLGA hybrid micelle.
This result suggests that the characteristics of the targeting used by antibody may be
expected to have an additive effect of the function of Fab0 itself in addition to the
increase in the intracellular uptake efficiency by cell recognition. In some anti-
bodies, the target protein knockdown effect is dramatically obtained using Fab0-
PLGA/siRNA-PLGA mixed micelle (data not shown). From these results, Fab0-
PLGA/siRNA-PLGA mixed micelles are believed to be useful as one of the targeting
formulations to recognize the target cell.
3. Expected side effect caused by gene therapy and limitation of
assessment using animal
3.1 Off-target effects caused by RNAi
The technique of RNAi in the medical field is expected to have not only thera-
peutic effects for human induced by knock-down specific genes but also suffers
from off-target effects. Previous study reported that algorithm or open-source
desktop software was developed to design RNAi sequences to exert strong and
selective suppression of target genes and predict off-target [45, 46]. However, it is
difficult to predict specific side effects that appear due to off-target effects in
human. Furthermore, we suggested that the details of the off-target effect are often
unclear due to the fact that commercial nucleic acid medications have a short period
of use. In some cases, mouse results may not be compatible with humans because
off-target effects vary by its sequences though there were no noticeable side effects
in our experiment in vivo.
3.2 Cytotoxicity of exogenous siRNA or polymer in development of
formulation
Until now, some polyplex or lipoplex with high membrane permeability
formulations have been used for siRNA delivery system [47, 48]. A number of
polymers have been popularly utilized to form stable and nanocomplexes with its
cytotoxicity problem [27, 49–53]. PEI is also probably the most frequently used
polycation in gene delivery, our LPEI-coated micelles did not exhibit cytotoxic
effects. The fact that no toxicity was found in our experiments at the concentrations
we used was consist with previous reports [54]. The greatest feature of this micelle
is that it consists of a safe polymer, PLGA. PLGA is known as one of the biodegrad-
able polymers used in marketed medication [55]. In some cases, siRNA can be
immunogenic such as virus vectors induce multiple component of the immune
response, cytotoxic T-lymphocyte (CTL) response can be elicited against viral gene
products of exogenous transgene products [25]. Regarding the immunogenicity of
this micelle, it is unlikely that immunogenicity was shown due to the fact that
cytokines in the peritoneal fluid were suppressed.
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3.3 Limitation of assessment using animal
In the future as a next step, immunodeficient mice would be indispensable when
we establish human model such as patient-derived xenograft (PDX) model. How-
ever, there is possibility that we cannot comprehend whether the micelle has med-
ical potential when immunodeficient mice are used because GPC3 might be a
molecule that is strongly associated with the immune system. That is why, we
considered that we should further examine the usefulness of this therapy using
micelles for human cancer cells based on our data using murine cell because there
are different characteristics between murine and human cancer cells.
4. Conclusion
In conclusion, our results could indicate that Gpc3 gene silencing using siRNA
has a possibility as an effective new therapeutic approach without side effects in
ovarian cancer, especially CCC with GPC3 expression. Furthermore, this GPC3
targeting gene therapy is also useful for high GPC3 expression cancer such as HCC,
melanoma and lung cancer if appropriate carrier is developed to deliver siRNA to
target cancer cell by i.v. in the future.
In addition, this finding is the first study to show that siRNA-PLGA hybrid
micelles can effectively deliver siRNA to cancer cells in vivo at a low dose with
significant anti-metastatic effect on murine ovarian cancer. We expect that novel
formulation with more specific effects like siRNA including drug delivery system
would be developed for malignant ovarian cancer therapy in the future.
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